Development of PET and SPECT Ligands for Brain Imaging (SBIR [R43/R44])
The summary for the Development of PET and SPECT Ligands for Brain Imaging (SBIR [R43/R44]) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Development of PET and SPECT Ligands for Brain Imaging (SBIR [R43/R44]): -Purpose. This Funding Opportunity Announcement (FOA) is intended to stimulate the commercial development of novel radioligands for positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging in human brain, and to incorporate pilot or clinical feasibility evaluation in pre-clinical studies, model development, or clinical studies. The NIH institutes listed in this FOA are specifically interested in the development of radioligands for molecular targets (e.g., receptors, cell adhesion molecules, intracellular messengers, and disease related proteins) that are of broad interest to the scientific community. These radiotracers will be used for neuroimaging as well as potential biological markers and surrogate endpoints for translational and clinical research, drug discovery and development, and clinical trials. Also appropriate for this FOA are applications proposing research and development of new technologies for radiotracer development. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications.
Federal Grant Title: | Development of PET and SPECT Ligands for Brain Imaging (SBIR [R43/R44]) |
Federal Agency Name: | National Institutes of Health |
Grant Categories: | Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | PA-08-137 |
Type of Funding: | Grant |
CFDA Numbers: | 93.173 |
CFDA Descriptions: | Research Related to Deafness and Communication Disorders |
Current Application Deadline: | May 07, 2011 |
Original Application Deadline: | May 07, 2011 |
Posted Date: | Apr 09, 2008 |
Creation Date: | Jan 26, 2009 |
Archive Date: | Jun 07, 2011 |
Total Program Funding: | |
Maximum Federal Grant Award: | |
Minimum Federal Grant Award: | |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
- Applicants Eligible for this Grant
- Small businesses
- Link to Full Grant Announcement
- Information not provided
- Grant Announcement Contact
- NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]] - Similar Government Grants
- • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...
- • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...
- • Medical Rehabilitation Research Resource (P50 Clinical Trial Optional)
- • Optimizing Health of Children and Adolescents with Perinatal HIV Exposure (U19 Clinical Tr...
- • BRAIN Initiative: Next-Generation Devices for Recording and Modulation in the Human Centr...
- • NIDCD Patient-Oriented Research Grant (R21)
- • Cell Lineage and Developmental Studies in Hearing and Balance
- • Structural Analyses of the Ligand-Binding Properties of Taste and Smell Receptors
- More Grants from the National Institutes of Health
- • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...
- • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...
- • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...
- • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional)
- • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...